Free Trial
NYSE:CVM

CEL-SCI (CVM) Stock Price, News & Analysis

CEL-SCI logo
$0.21 +0.01 (+4.07%)
As of 01:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About CEL-SCI Stock (NYSE:CVM)

Key Stats

Today's Range
$0.18
$0.21
50-Day Range
$0.20
$0.51
52-Week Range
$0.18
$2.39
Volume
912,817 shs
Average Volume
946,424 shs
Market Capitalization
$16.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Remove Ads
Receive CVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CEL-SCI and its competitors with MarketBeat's FREE daily newsletter.

CVM Stock News Headlines

CEL-SCI (NYSE:CVM) Now Covered by Analysts at StockNews.com
CEL-SCI publishes new data from Multikine study
EU’s Action Takes Aim At US Retirees
Trump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and global powers like China, Russia, and even Europe rapidly moving away from the U.S. dollar, central banks and financial giants are frantically buying gold at historic rates. This massive shift threatens your retirement savings with inflation and market instability—potentially worse than 2008. But you can protect yourself today by leveraging a little-known IRS loophole that lets you diversify your IRA or 401(k) into gold—tax-free and penalty-free.
CEL-SCI Announces Closing of $2.5 Million Offering
CEL-SCI announces pricing of $2.56M common stock offering
CEL-SCI Announces Pricing of $2.5 Million Offering
See More Headlines

CVM Stock Analysis - Frequently Asked Questions

CEL-SCI's stock was trading at $0.3999 at the start of the year. Since then, CVM stock has decreased by 50.5% and is now trading at $0.1980.
View the best growth stocks for 2025 here
.

CEL-SCI Co. (NYSE:CVM) issued its quarterly earnings results on Thursday, August, 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01.

CEL-SCI's stock reverse split on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 14th 2017. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of CVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CEL-SCI investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Pfizer (PFE), Canopy Growth (CGC) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
8/15/2024
Today
4/04/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:CVM
Employees
43
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-26,920,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.15 per share
Price / Book
1.38

Miscellaneous

Free Float
64,673,000
Market Cap
$16.58 million
Optionable
Optionable
Beta
0.95
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NYSE:CVM) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners